

David Pryor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8413704/publications.pdf>

Version: 2024-02-01

53
papers

1,153
citations

471509

17
h-index

414414

32
g-index

54
all docs

54
docs citations

54
times ranked

1889
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT. <i>Medical Dosimetry</i> , 2022, 47, 61-69.	0.9	1
2	Large variation in conservative management of low-risk prostate cancer in Australia and New Zealand. <i>BJU International</i> , 2022, 130, 17-19.	2.5	5
3	Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma – The RAPPOR Trial. <i>European Urology</i> , 2022, 81, 364-372.	1.9	70
4	Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 873-884.	2.8	16
5	Intrafraction cone beam computed tomography verification of breath hold during liver stereotactic radiation therapy. <i>Journal of Medical Radiation Sciences</i> , 2021, 68, 52-59.	1.5	8
6	A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPOR): Clinical trial protocol. <i>Contemporary Clinical Trials Communications</i> , 2021, 21, 100703.	1.1	6
7	Stereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, 65, 365-373.	1.8	7
8	Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, 65, 956-968.	1.8	12
9	Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer. <i>Radiation Oncology</i> , 2021, 16, 142.	2.7	8
10	Automatic radiotherapy delineation quality assurance on prostate MRI with deep learning in a multicentre clinical trial. <i>Physics in Medicine and Biology</i> , 2021, 66, 195008.	3.0	7
11	Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New Zealand. <i>JAMA Network Open</i> , 2021, 4, e2129647.	5.9	13
12	Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). <i>Practical Radiation Oncology</i> , 2020, 10, e136-e146.	2.1	41
13	Quality and access – Early experience of implementing a virtual stereotactic chart round across a national network. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 422-426.	1.8	7
14	A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer. <i>BJU International</i> , 2019, 124, 31-36.	2.5	27
15	OC-0277 Interim safety analysis of RAPPOR trial - SABR with pembrolizumab in oligometastatic RCC. <i>Radiation Therapy and Oncology</i> , 2019, 133, S137.	0.6	1
16	SP-0677 Oligometastatic Prostate SBRT: The How, What, Where and When. <i>Radiation Therapy and Oncology</i> , 2019, 133, S355-S356.	0.6	0
17	EP-1543 Early Results of a Phase 2 Multicentre Study of Linac-based Stereotactic Boost for Prostate Cancer. <i>Radiation Therapy and Oncology</i> , 2019, 133, S832-S833.	0.6	0
18	Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. <i>Radiation Therapy and Oncology</i> , 2019, 140, 68-75.	0.6	20

#	ARTICLE	IF	CITATIONS
19	Phase 2 Multicenter Study of Gantry-Based Stereotactic Radiotherapy Boost for Intermediate and High Risk Prostate Cancer (PROMETHEUS). <i>Frontiers in Oncology</i> , 2019, 9, 217.	2.8	30
20	TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adjuvant Androgen deprivation: NINJA study protocol. <i>BMJ Open</i> , 2019, 9, e030731.	1.9	18
21	MA01.01 Safety of Pembrolizumab Combined with Stereotactic Ablative Body Radiotherapy (SABR) for Pulmonary Oligometastases. <i>Journal of Thoracic Oncology</i> , 2019, 14, S248.	1.1	1
22	Moderate hypofractionation for prostate cancer: A user's guide. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 232-239.	1.8	11
23	Development of Indicators to Assess Quality of Care for Prostate Cancer. <i>European Urology Focus</i> , 2018, 4, 57-63.	3.1	17
24	Evaluation of kidney motion with and without a pneumatic abdominal compression belt: Considerations for stereotactic radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 128-132.	1.8	2
25	TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II. <i>BMC Cancer</i> , 2018, 18, 1030.	2.6	50
26	Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method. <i>Radiotherapy and Oncology</i> , 2018, 128, 308-314.	0.6	12
27	PO-0823: TRAC: Automated atlas based machine learning QA of contouring accuracy for the PROMETHEUS trial. <i>Radiotherapy and Oncology</i> , 2018, 127, S429-S430.	0.6	2
28	PROstate Multicentre External beam radioTHERapy Using a Stereotactic boost: the PROMETHEUS study protocol. <i>BMC Cancer</i> , 2018, 18, 588.	2.6	16
29	Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. <i>Radiotherapy and Oncology</i> , 2018, 129, 377-386.	0.6	39
30	Utility of ⁶⁸ Ga prostate specific membrane antigen α positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 372-378.	1.8	83
31	Vector-model-supported approach in prostate plan optimization. <i>Medical Dosimetry</i> , 2017, 42, 79-84.	0.9	4
32	Stereotactic radiotherapy for primary renal cell carcinoma: time for larger scale prospective studies. <i>BJU International</i> , 2017, 120, 603-604.	2.5	0
33	A Comparison of Non-coplanar Three-dimensional Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, and Volumetric Modulated Radiation Therapy for the Delivery of Stereotactic Ablative Radiation Therapy to Peripheral Lung Cancer. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2017, 48, 360-369.	0.3	3
34	Improving plan quality for prostate volumetric-modulated arc therapy. <i>Medical Dosimetry</i> , 2017, 42, 348-356.	0.9	7
35	Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases. <i>Chinese Clinical Oncology</i> , 2017, 6, S17-S17.	1.2	16
36	Stereotactic spine radiosurgery: Review of safety and efficacy with respect to dose and fractionation. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 8, 30.		47

#	ARTICLE	IF	CITATIONS
37	Variants of EVER1 and EVER2 (TMC6 and TMC8) and human papillomavirus status in patients with mucosal squamous cell carcinoma of the head and neck. <i>Cancer Causes and Control</i> , 2016, 27, 809-815.	1.8	11
38	The effect of beam arrangements and the impact of non-coplanar beams on the treatment planning of stereotactic ablative radiation therapy for early stage lung cancer. <i>Journal of Medical Radiation Sciences</i> , 2016, 63, 31-40.	1.5	13
39	A comparison of three different VMAT techniques for the delivery of lung stereotactic ablative radiation therapy. <i>Journal of Medical Radiation Sciences</i> , 2016, 63, 23-30.	1.5	9
40	Development of an International Prostate Cancer Outcomes Registry. <i>BJU International</i> , 2016, 117, 60-67.	2.5	31
41	Evaluating the accuracy of the XVI dual registration tool compared with manual soft tissue matching to localise tumour volumes for post-prostatectomy patients receiving radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 527-534.	1.8	10
42	Long-term results of positron emission tomography-directed management of the neck in node-positive head and neck cancer after organ preservation therapy. <i>Oral Oncology</i> , 2015, 51, 260-266.	1.5	24
43	Human papillomavirus status and p16INK4A expression in patients with mucosal squamous cell carcinoma of the head and neck in Queensland, Australia. <i>Cancer Epidemiology</i> , 2015, 39, 174-181.	1.9	45
44	Outcomes after primary chemoradiotherapy for N3 (>6 cm) head and neck squamous cell carcinoma after an FDG-PET-guided neck management policy. <i>Head and Neck</i> , 2014, 36, 1200-1206.	2.0	17
45	Circulating tumor cell detection in high-risk non-metastatic prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 2157-2162.	2.5	50
46	T-category Remains an Important Prognostic Factor for Oropharyngeal Carcinoma in the Era of Human Papillomavirus. <i>Clinical Oncology</i> , 2014, 26, 643-647.	1.4	4
47	Economic analysis of FDG-PET-guided management of the neck after primary chemoradiotherapy for node-positive head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2013, 35, 1287-1294.	2.0	28
48	Does fluorodeoxyglucose PET add to the management of the neck following curative radiotherapy in head and neck cancer compared with computed tomography?. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 279-284.	2.4	3
49	The emerging era of personalized therapy in squamous cell carcinoma of the head and neck. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 236-251.	1.1	19
50	Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2011, 47, 984-987.	1.5	12
51	Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. <i>Head and Neck</i> , 2011, 33, 1675-1682.	2.0	155
52	Magnetic resonance spectroscopy as a decision tool in multimodality treatment design for localised prostate cancer. <i>Oncology Reviews</i> , 2009, 3, 215-223.	1.8	0
53	Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2009, 90, 172-176.	0.6	113